



IP7 Rec'd PCT/PTO 03 APR 2006

PCT

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	H. SINGS et al.		
Serial No.:	10/560,290	Case No.:	21278P
Filed:	December 12, 2005		
For:	PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS		

Art Unit:

1625

Examiner:

-

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 2233-1450

Attention: Office of Initial Patent Examination -
Filing Receipt Corrections

REQUEST FOR CORRECTED FILING RECEIPT
IN A U.S. NATIONAL PHASE APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By David Brown Date March 30, 2006

Sir:

Attached is a copy of the official filing receipt received from the Patent and Trademark Office in the above application for which issuance of a corrected filing receipt is respectfully requested.

There is an error with respect to the city and state of co-inventor HEATHER SINGS. The correct city and state of HEATHER SINGS is West Windsor, NJ, and not "Rahway, NJ" as erroneously shown on the filing receipt.

There is also an error with respect to the city and state of co-inventor FEROZE UJJAINWALLA. The correct city and state of FEROZE UJJAINWALLA is Scotch Plains, NJ, and not "Rahway, NJ" as erroneously shown on the filing receipt.


Applicants had correctly recited the city and state for the co-inventors on the accompanying copy of the Declaration and Power of Attorney which had been submitted with the transmittal for the filing of this U.S. national phase application under 35 U.S.C. 371. For your convenience, a copy of the Declaration and Power of Attorney and the accompanying transmittal letter to the U.S. Designated/Elected Office are enclosed.

Serial No.: 10/560,290
Case No.: 21278P
Page No.: 2

Since this correction is not due to any error by the Applicants, it is believed that no further fee is due. Nonetheless, should a fee be due, please charge the additional fee to deposit account 13-2755.

Respectfully submitted,

By



Baerbel R. Brown, Reg. No. 47,449
Attorney for Applicants

/agb
Enclosure

Merck & Co., Inc.
P.O. Box 2000
Rahway, New Jersey 07065
Tel.: (732)594-0672

March 29, 2006


 PAT. REG. COORD.
 DOCKET
 ATTORNEY
 MAINTENANCE
 TRADEMARK OFFICE
 CASE REFERENCE CLERK
 OTHER

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/560,290	12/12/2005	1625	1050	21278P		24	1

 210
 MERCK AND CO., INC
 P O BOX 2000
 RAHWAY, NJ 07065-0907


CONFIRMATION NO. 3338

FILING RECEIPT



OC000000018257001

Date Mailed: 03/15/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 Heather Sings, ~~Rahway, NJ~~ West Windsor, NJ
 Feroze Ujjainwalla, ~~Rahway, NJ~~ Scotch Plains, NJ

Power of Attorney: The patent practitioners associated with Customer Number 210.

Domestic Priority data as claimed by applicant

 This application is a 371 of PCT/US04/22911 07/16/2004
 which claims benefit of 60/489,313 07/22/2003

Foreign Applications

If Required, Foreign Filing License Granted: 03/09/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/560,290**
Projected Publication Date: 06/15/2006

Non-Publication Request: No

Early Publication Request: No

 MAR 27 2006
 PATENT & TRADEMARK OFFICE

Piperidine derivatives as melanocortin-4 receptor agonists

Preliminary Class

546

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof